KIORA PHARMACEUTICALS Files 8-K for Reg FD, Financials

Ticker: KPHMW · Form: 8-K · Filed: Feb 12, 2024 · CIK: 1372514

Kiora Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyKiora Pharmaceuticals Inc (KPHMW)
Form Type8-K
Filed DateFeb 12, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance, 8-K

TL;DR

**KPRX filed a routine 8-K for Reg FD and financials, showing standard compliance.**

AI Summary

KIORA PHARMACEUTICALS, INC. filed an 8-K on February 12, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that the company, trading under KPRX on NASDAQ, is maintaining its compliance with SEC regulations. For investors, this matters because it signals ongoing transparency and adherence to disclosure requirements, which can build confidence in the company's operations and management.

Why It Matters

This filing demonstrates KIORA PHARMACEUTICALS' commitment to regulatory compliance and transparency, which is crucial for investor confidence and maintaining its NASDAQ listing.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no immediate negative or positive financial implications disclosed.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material changes to the company's financial health or operations, and would continue to monitor for more substantive disclosures like earnings reports or clinical trial updates.

Key Numbers

  • February 12, 2024 — Date of Report (The date of the earliest event reported in the 8-K filing.)
  • 001-36672 — Commission File Number (The SEC file number for KIORA PHARMACEUTICALS, INC.)
  • 98-0443284 — IRS Employer Identification No. (The IRS Employer Identification Number for KIORA PHARMACEUTICALS, INC.)
  • $0.01 — par value (The par value of the Common Stock of KIORA PHARMACEUTICALS, INC.)

Key Players & Entities

  • KIORA PHARMACEUTICALS, INC. (company) — registrant
  • KPRX (company) — trading symbol
  • NASDAQ (company) — exchange where registered
  • February 12, 2024 (date) — date of earliest event reported
  • Delaware (company) — state of incorporation
  • 001-36672 (dollar_amount) — Commission File Number
  • 98-0443284 (dollar_amount) — IRS Employer Identification No.
  • 332 Encinitas Blvd. Suite 102 Encinitas , CA 92024 (company) — Registrant's business address
  • 858-224-9600 (dollar_amount) — Registrant's telephone number

Forward-Looking Statements

  • KIORA PHARMACEUTICALS will continue to file routine compliance documents. (KIORA PHARMACEUTICALS, INC.) — high confidence, target: 2024-12-31

FAQ

What is the primary purpose of this 8-K filing by KIORA PHARMACEUTICALS, INC.?

The primary purpose of this 8-K filing by KIORA PHARMACEUTICALS, INC. is to disclose information under Regulation FD and to file financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits' sections.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is February 12, 2024, as stated in the 'Date of report (Date of earliest event reported): February 12, 2024' section.

What is the trading symbol and the exchange on which KIORA PHARMACEUTICALS, INC.'s Common Stock is registered?

KIORA PHARMACEUTICALS, INC.'s Common Stock, with a $0.01 par value, trades under the symbol KPRX and is registered on NASDAQ, as detailed under 'Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock, $0.01 par value KPRX NASDAQ'.

Is KIORA PHARMACEUTICALS, INC. classified as an emerging growth company?

No, KIORA PHARMACEUTICALS, INC. is not classified as an emerging growth company, as indicated by the unchecked box 'Emerging growth company ☐' in the filing.

What is the business address and telephone number of KIORA PHARMACEUTICALS, INC.?

The business address of KIORA PHARMACEUTICALS, INC. is 332 Encinitas Blvd. Suite 102 Encinitas, CA 92024, and its telephone number is (858) 224-9600, as listed in the filing's business address and phone sections.

Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-02-12 17:23:39

Key Financial Figures

  • $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Kiora Pharmaceuticals, Inc. (the "Company") hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use in presentations to investors from time to time. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference. The information furnished in this report, including Exhibit 99.1, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Company Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Executive Vice President of Finance (Principal financial and accounting officer) Date: February 12, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.